Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 12, 2009, Pages 1525-1530

  Kuna, Andrea Tesija ^a   Lamot, Lovro ^b   Miler, Marijana ^a   Harjacek, Miroslav ^b   Simundic, Ana Maria ^a   Vrkic, Nada ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b Croatia   (Croatia)

Author keywords

Antibodies to mutated citrullinated vimentin; Citrullinated proteins; Juvenile idiopathic arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTHROPATHY; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; JOINT ASPIRATION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYARTICULAR DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY;

ANTIBODIES; ARTHRITIS, JUVENILE RHEUMATOID; CASE-CONTROL STUDIES; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MUTATION; PEPTIDES, CYCLIC; VIMENTIN;

EID: 73249141041     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.288     Document Type: Article

References (42)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-778
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J Rheumatol 2004;31:390-392
3. Migliorini P, Pratesi F, Tommasi C, Anzilotti C. The immune response to citrullinated antigens in autoimmune diseases. Autoimmun Rev 2005;4:561-564
4. Tesija Kuna A, Zirovic M. Antibodies to citrullinated proteins/peptides in rheumatoid arthritis: what have we learned so far? Biochemia Medica 2008;18:275-290
5. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43: 155-163
6. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004;350:17-34.
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-851
8. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-1089
9. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5-year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-1749
10. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142-50.
11. Vossenar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004;63:373-381
12. Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, et al. Mutation and citrullination modify vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511
13. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:R119.
14. Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007;34:1658-1663
15. Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, et al. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis. Protein Pept Lett 2008;15:314-317
16. Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008;10:R12.
17. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53:498-504.
18. Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Ben Fredj H, Sammound S, et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int 2008;29:59-62.
19. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd-and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007;53:1527-1533
20. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002;61:608-611
21. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004;31:1829-1833
22. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 2008;37:849-857
23. Giannini EH, Lovell DJ, Felson DT, Goldsmith CH. Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 1994;37(Suppl):S428.
24. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209
25. Harjacek M, Ruperto N, Ostojic J, Bukovac LT. The Croatian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheum 2001;19:S40-4.
26. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-1064
27. Ringold S, Wallace CA. Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol 2007;19:471-476
28. Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:3087-3095
29. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alphaand beta-chains of fibrin. J Immunol 2001;166:4177-4184
30. Suzuki A, Yamad R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K. Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun 2005;333: 418-426
31. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 2005;44:1374-1382
32. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated a-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421-9.
33. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allerg Immunol 2008;34:4-10.
34. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.
35. Innala L, Kokkonen H, Eriksson C, Jiddell E, Berglin E, Rantapaa-Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1-7.
36. Machado SH, von Mühlen CA, Brenol JC, Bisotto L, Xavier RM. The prevalence of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. J Pediatr (Rio J) 2005;81:491-494
37. Van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile rheumatoid arthritis. J Rheumatol 2003;30:825-828 (Pubitemid 36402779)
38. Hassfeld WG, Vinje O, König K, Bayer PM, Förre Ö, Dunky A. Autoantibodies to mutated citrullinated vimentin in juvenile rheumatoid arthritis. Ann Rheum Dis 2006; 65(Suppl II):439.
39. Guseinova D, Lazareva A, Shantere R, Berzinja D, Rasnachs O, Stanevicha V. The value of antibodies against mutated citrullinated vimentin in juvenile idiopathic arthritis. Pediatr Rheumatol 2008;6(Suppl I):P67.
40. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-3494
41. van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008;58:53-60.
42. Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, et al. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum 2006;55:53-56